Abstract Background and hypothesis: Cannabis use initiation during adolescence has increased globally, raising concerns about neurodevelopmental consequences during this critical…
Abstract Cannabis use represents a significant environmental risk factor for psychotic disorders, with emerging evidence suggesting complex interactions between cannabinoid…
Abstract Highlights: What are the main findings? What are the implications of the main finding? Abstract: Objective: To scope the…
Abstract Background: Recent drug enforcement activities have possibly suggested the presence of some calcium channel blocker antihypertensives in association with…
Abstract Background: Methylphenidate (MPH), a central nervous system stimulant primarily prescribed for attention-deficit/hyperactivity disorder (ADHD), has seen increasing rates of…
Abstract Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways related to appetitive behavior. Hence, this…
Abstract Background: Natural Cannabis (NC) and Synthetic Cannabinoids (SCs) use can increase the risk and exacerbate the course of psychotic…
Abstract Background: The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses.…
Abstract Background: Lurasidone is an atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia. Recently, lurasidone was also…
Abstract BACKGROUND: Following the development of the coronavirus disease-2019 (COVID-19) pandemic in Italy, a strict lockdown was imposed from March…